Embed Size (px)
Citation preview
Non-melanoma skin cancer• 3.5M cases per year in USA.
• principal cause – UV from
sunlight.
Current solution: UV protection
• Sun care protects from UV induced skin cancer.
• Only UV protector clinically proven to reduce skin cancer incidence.
Need• Sun care that moves beyond sun
protection factor (SPF).
Drivers
• Consumer preference.• Medical need.• Legal requirements.
Occupational health – sun care
Our solution• Adds active cancer prophylaxis to
sun care.• Prevents 80% of UV induced skin
cancer (mouse tests).• Non-toxic natural compound.
Uniqueness:Targeting cell polarity.
We seek funds to:• Complete final animal tests.• Formulate.• Clinical trials completing efficacy
studies.
Complete financing need 2.5 M€.
How? Affordable development in a high cost space.• Established ingredients.• Accelerated clinical tests in
established high need patient populations.
• Global selection of high need geographies.
Global market size• Specialist products for high need
populations: 100M US$.• OTC products: 10B US$.
IP• Secondary medical indication1.• Formulation.• Other e.g. packaging.
(1) Provisional patent applications PT2014000049856 and PT2014000177080.
Competition
high SPFclinically provenanti-canceranti-cancer & beyond SPF
SPF50
Next plans• Tests & formulation (6 months).• Proof of concept in patients (phase 2a; 6-24 months).• Licensing/sale.
Financing need: 2.5M €.
Team
Richard Hampson• University of London, Harvard University.• Oryzon, Barcelona.• Lead promoter since 2009.Rui Martinho• University of Sussex, New York University.• Instituto Gulbenkian, University Algarve.• Co-promoter since 2009.
Advisors – sun care• Skin cancer center, Charité Hospital, Berlin.• The team behind:
Advisors mean expertise:
• Dispensers.
• High need population already recruited.• Non-invasive clinical monitoring. • Regulatory needs: the US market.
